Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Knightscope
Sponsored
content by Knightscope
MA
MarketJar
Community Contributor
The Next Phase of Defense AI: A Robotic Response to America’s Security Gaps
Autonomous systems are no longer just a futuristic vision — they’re fast becoming an essential layer of national security. As AI reshapes everything from finance to warfare, physical security remains one of the most under-addressed frontiers.
View narrative
US$12.00
FV
50.7% undervalued
intrinsic discount
22.00%
Revenue growth p.a.
Set Fair Value
9
users have liked this narrative
1
users have commented on this narrative
42
users have followed this narrative
8 days ago
author updated this narrative
Figma
TI
TickerTickle
Community Contributor
Figma (FIG): The S&P 500’s Design Standard Turning Into an All-in-One Platform
Watching Figma Grow Up I’ve been using Figma almost every single day for the past five years. As a product designer, it’s been my main tool for designing interfaces, testing and prototyping ideas, and also for working together with teams in different countries and time zones.
View narrative
US$65.70
FV
8.5% overvalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
19
users have followed this narrative
Updated
narrative
Sleep Cycle
MA
Mandelman
Community Contributor
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Update Q1 2025 (updated 250510) The latest user‐growth data suggest headwinds for top-line revenue, but management’s active repricing initiatives should help offset this. By combining modest user gains with targeted price increases, the company can still drive overall revenue growth.
View narrative
SEK 38.04
FV
19.7% undervalued
intrinsic discount
3.15%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
2
users have commented on this narrative
37
users have followed this narrative
Updated
narrative
JB Hi-Fi
RO
Robbo
Community Contributor
Has JB Hi-Fi Lost Its Point of Difference?
I may be showing my age here, but I feel that a decade or so ago, shopping at JB Hi-Fi was a different experience. There seemed to be a deliberate policy of employing sales staff from alternative subcultures, which gave the stores a unique, edgy vibe.
View narrative
AU$76.00
FV
51.6% overvalued
intrinsic discount
-0.45%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
1
users have commented on this narrative
11
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Apellis Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 18 Analysts
Expanded Labels And Complement Pipeline Will Capture Global Aging Markets
Key Takeaways EMPAVELI and SYFOVRE are positioned to capture dominant market shares and drive sustained revenue growth through broad adoption and durable clinical efficacy. Advances in pipeline therapies and operational discipline strengthen both profit margins and long-term earnings leverage, setting Apellis apart from industry peers.
View narrative
US$60.00
FV
53.3% undervalued
intrinsic discount
23.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
ME Group International
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Photobooth Decline Will Persist As Digital Shifts Will Soften Downside
Key Takeaways Heavy dependence on expanding machine installations and pay-per-use transactions exposes the company to revenue volatility if demand softens or markets saturate. Digital adoption and automation trends threaten the core photobooth business, risking structural revenue declines and increased competition from tech-savvy service providers.
View narrative
UK£2.35
FV
15.2% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Monde Nissin
AN
AnalystHighTarget
Consensus Narrative from 11 Analysts
Urbanization And Digitalization Will Drive Quorn Market Leadership
Key Takeaways Rapid gross margin expansion, supply chain overhaul, and SKU rationalization are likely to drive earnings and profitability beyond current expectations. Strong growth in Meat Alternatives and dominance in core segments, supported by digital distribution and innovation, position the company for sustained high-margin revenue growth.
View narrative
₱13.28
FV
45.5% undervalued
intrinsic discount
6.71%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Medco Energi Internasional
AN
AnalystLowTarget
Consensus Narrative from 12 Analysts
Rising Decarbonization And Debt Will Shrink Margins But Enable Resilience
Key Takeaways Exposure to energy transition risks and renewables growth threatens Medco's long-term fossil fuel demand, reserve stability, and future earnings sustainability. High leverage, refinancing dependence, and market volatility may increase funding costs and limit growth opportunities as ESG expectations rise.
View narrative
Rp1.31k
FV
8.5% undervalued
intrinsic discount
-5.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
FTAI Aviation
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Reliance On Legacy Engines Will Reduce Margins As Decarbonization Accelerates
Key Takeaways Heavy dependence on legacy engine platforms and aftermarket demand exposes FTAI Aviation to structural risks from new technology and industry shifts. Aggressive expansion and global integration introduce operational challenges that may compress margins and undermine future earnings stability.
View narrative
US$147.00
FV
5.7% overvalued
intrinsic discount
13.85%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Zai Lab
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
China And Asia-Pacific Demographics Will Transform Biopharma Markets
Key Takeaways Accelerated product launches, innovation, and strategic market expansion position Zai Lab for rapid revenue and margin growth beyond current analyst expectations. Strong operational model and international focus could transform Zai Lab into a leading global biopharma player, attracting premium valuations and partnership opportunities.
View narrative
US$75.00
FV
57.0% undervalued
intrinsic discount
59.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Datavault AI
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
AI-Driven Data Exchanges And IBM Alliance Will Transform Markets
Key Takeaways Strategic partnerships, proprietary technology, and acquisitions position Datavault AI for robust, high-margin recurring revenue growth across diverse, regulated data markets. Compliance-first infrastructure and alliances with industry leaders enable scalable, secure solutions tailored to capitalize on accelerating digital transformation and shifting market regulations.
View narrative
US$3.00
FV
86.9% undervalued
intrinsic discount
176.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
New
narrative
Cronos Group
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Global Cannabis Legalization Will Expand Wellness And Medicine Markets
Key Takeaways Strong premium brand portfolio, international expansion, and R&D investments position Cronos for sustainable margin growth and increased global market share as cannabis normalization accelerates. Robust financial health and strategic partnerships set Cronos up as a leading consolidator with significant upside from licensing, M&A, and new revenue streams.
View narrative
CA$5.00
FV
28.6% undervalued
intrinsic discount
6.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Zedcor
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Cyclical Reliance Will Squeeze Margins Yet Uncover Modest Promise
Key Takeaways Reliance on cyclical industries and evolving technology trends could lead to unpredictable revenues and limit long-term growth opportunities. High capital needs, potential rising costs, and competitive pressures threaten profitability and could erode market advantage over time.
View narrative
CA$5.00
FV
11.8% undervalued
intrinsic discount
59.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies